Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) was up 5.4% during mid-day trading on Friday . The company traded as high as $4.96 and last traded at $4.85. Approximately 323,001 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 486,688 shares. The stock had previously closed at $4.60.
Eliem Therapeutics Trading Up 5.4%
The firm’s 50 day simple moving average is $2.38 and its 200-day simple moving average is $1.98. The stock has a market capitalization of $144.30 million, a price-to-earnings ratio of -9.15 and a beta of -0.39.
About Eliem Therapeutics
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
See Also
- Five stocks we like better than Eliem Therapeutics
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Do you know what Amazon is planning for January 1?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
